Nucleic acid sequences showing enhanced expression in benign neuroblastoma compared with acritical human neuroblastoma
AssigneesHisamitsu Pharmaceutical Co., Inc., Chiba-Perfecture
InventorAkira Nakagawara
Life of this patent
Estimating the term…
Abstract
Nucleic acids originating in a gene which is expressed in human neuroblastoma, characterized by showing enhanced expression in benign human neuroblastoma compared with in acritical human neuroblastoma and having a sequence selected from among the group consisting of the nucleic acid sequences represented by SEQ ID NOS: 1 to 104 in Sequence Listing; nucleic acids complementary with the above nucleic acids; fragments of these nucleic acids; use thereof as a probe or a primer; and diagnosis of the prognosis of human neuroblastoma with the use of any of the same.
Claims10
A nucleic acid derived from a gene expressed in human neuroblastoma, the nucleic acid comprising a sequence selected from the group consisting of the nucleic acid sequences set forth in SEQ ID NO:
- 1 to NO:
- 104 in the Sequence Listing, or a complementary nucleic acid thereof.
A nucleic acid derived from a gene whose expression is enhanced in human neuroblastoma with favorable prognosis based on comparison between human neuroblastoma with favorable prognosis and human neuroblastoma with unfavorable prognosis, the nucleic acid comprising a sequence selected from the group consisting of the nucleic acid sequences set forth in SEQ ID NO:
- 1 to NO:
- 104 in the Sequence Listing, or a complementary nucleic acid thereof.
Dependencies are inferred from the claim text.